Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.

doi:10.1038/s43018-020-00140-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.

Nature cancer - 1 Dec 2020

Cummings Amy L, Gukasyan Jaklin, Lu Henry Y, Grogan Tristan, Sunga Gemalene, Fares Charlene M, Hornstein Nicholas, Zaretsky Jesse, Carroll James, Bachrach Benjamin, Akingbemi Wisdom O, Li Debory, Noor Zorawar, Lisberg Aaron, Goldman Jonathan W, Elashoff David, Bui Alex A T, Ribas Antoni, Dubinett Steven M, Rossetti Maura, Garon Edward B

Abstract excerpt

Human leukocyte antigen (HLA)-B has been recognized as a major determinant of discrepancies in disease outcomes, and recent evidence indicates a role in immune checkpoint blockade (ICB) efficacy. The B44 supertype, which features an electropositive binding pocket that preferentially displays peptides with negatively charged amino acid anchors, is associated with improved survival in ICB-treated melanoma. Yet this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glutamic Acid

Share to HLA-B Antigens

Share to HLA-B44 Antigen

Share to Immunotherapy

Share to Lung Neoplasms

Share to Melanoma

Share to Mutation

Source

Open in PubMed

Identifiers

PMID: 35121931
DOI: 10.1038/s43018-020-00140-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.PMID 35121931Read ↗

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.Semantic proximity Read ↗

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Ensuring equity in the era of HLA-restricted cancer therapeuticsSemantic proximity Read ↗

Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.Semantic proximity Read ↗

Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapySemantic proximity Read ↗

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine designSemantic proximity Read ↗

A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.